Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically.

Autor:	Bardakci M; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey., Demirtas Esmer D; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey., Hafizoglu E; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey., Yaslikaya S; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey., Genc TB; Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey., Ozcelik M; Department of Medical Oncology, Umraniye Training and Research Hospital, Istanbul, Turkey., Erdat EC; Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Turkey., Hendem E; Department of Medical Oncology, Necmettin Erbakan University Meram Faculty of Medicine, Konya, Turkey., Buyukbayram ME; Department of Medical Oncology, Ataturk University Faculty of Medicine, Erzurum, Turkey., Alaca Topcu Z; Department of Medical Oncology, Medeniyet University Faculty of Medicine, Istanbul, Turkey., Kalkan Z; Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, Turkey., Yildirim N; Department of Medical Oncology, Firat University Faculty of Medicine, Elazig, Turkey., Celebi A; Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey., Ergun Y; Department of Medical Oncology, Batman World Hospital, Batman, Turkey., Paydas S; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey., Tatli AM; Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey., Karakas H; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey., Koseci T; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey., Sendur MAN; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
Jazyk:	angličtina
Zdroj:	Oncology [Oncology] 2023; Vol. 101 (11), pp. 723-729. Date of Electronic Publication: 2023 Jun 28.
DOI:	10.1159/000531722
Abstrakt:	Introduction: In the adjuvant treatment of low-risk stage III colon cancer treated surgically, 3 months of CAPOX followed by 3 months of capecitabine is not a common clinical practice. Since there are no data on this practice in the literature, we have no idea how often it is used. However, it should be noted that this application is used in some centers due to the cumulative neurotoxicity of oxaliplatin but there are insufficient data in the literature on its efficacy. Methods: The data of patients with colon cancer treated surgically who were followed up in 12 different oncology centers in Turkey between November 2004 and June 2022 were analyzed retrospectively. Results: The study included 194 patients. The treatment arms were as follows: 3 months of CAPOX followed by 3 months of capecitabine = arm A and CAPOX/FOLFOX (6 months) = arm B. There were 78 patients (40.2%) in arm A and 116 patients (59.8%) in arm B. The median age and sex distribution were similar between the treatment arms. The median follow-up period of all patients was 34.4 months (95% confidence interval, 29.1-39.7). When arm A was compared with arm B, 3-year disease-free survival (DFS) was 75.3% versus 88.4% and 5-year DFS was 75.3% versus 82.8%, respectively. There were similar DFS outcomes between the treatment arms (p = 0.09). Rates of any grade of neuropathy were numerically lower in arm A, but the difference between the treatment arms was not statistically significant (51.3% vs. 56.9%; p = 0.44). The frequency of neutropenia was similar between the treatment arms. Conclusion: In this study, the efficacy and safety of the 3 months of CAPOX followed by 3 months of capecitabine chemotherapy regimen in the adjuvant treatment of low-risk stage III colon cancer treated surgically were proven. This result may also support the discontinuation of oxaliplatin at 3 months while continuing fluoropyrimidines, which is a common clinical practice but lacks sufficient data. (© 2023 S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu